Development and characterization of a cancer-specific monoclonal antibody (CasMab) against podoplanin
Project/Area Number |
26440019
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Structural biochemistry
|
Research Institution | Tohoku University |
Principal Investigator |
Kaneko Mika 東北大学, 医学系研究科, 准教授 (00323163)
|
Co-Investigator(Renkei-kenkyūsha) |
KUNITA Akiko 東京大学, 大学院医学系研究科, 助教 (50608768)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | CasMab / PDPN / 腫瘍型糖鎖構造 / 糖転移酵素遺伝子 / 抗体医薬開発 / 糖転移酵素関連遺伝子 / 糖鎖 |
Outline of Final Research Achievements |
Podoplanin (PDPN) is a platelet aggregation-inducing mucin-like sialoglycoprotein that is highly expressed in many cancers and normal tissues. PDPN has also been reported to be a marker to enrich tumor-initiating cells. Recently, we established the platform to produce a cancer-specific mAb (CasMab) by combining glycobiology and cell engineering technologies. In this study, we also established glycan-deficient CHO-S and HEK-293T cell lines, using the CRISPR/Cas or TALEN. We investigate several novel cancer-specific anti-PDPN or anti-glycopeptide mAbs. Antitumor activity of chimeric anti-human PDPN antibodies were validated. The CasMab-producing platform could lead to establishment of the side effect-reducing mAbs.
|
Report
(4 results)
Research Products
(42 results)
-
[Journal Article] Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependentcellular cytotoxicity.2017
Author(s)
Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M,Fujii Y, Ogasawara S, Kato Y.
-
Journal Title
Cancer Med
Volume: -
Issue: 4
Pages: 768-777
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.2017
Author(s)
Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S,Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.
-
Journal Title
Monoclon Antib Immunodiagn Immunother.
Volume: 36(1)
Issue: 1
Pages: 20-24
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.2017
Author(s)
Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y.
-
Journal Title
Cancer Med.
Volume: 6(2)
Issue: 2
Pages: 382-396
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
[Journal Article] Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.2016
Author(s)
Abe S, Kato KM, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
-
Journal Title
Cancer Sci
Volume: 107(9)
Issue: 9
Pages: 1198-1205
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains.2016
Author(s)
Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.
-
Journal Title
Cancer Immunol Res.
Volume: 4(3)
Pages: 259-268
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.2015
Author(s)
Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Young MA, Deluca-Rapone L, Shienbaum AJ, Yin K, Jensen LD, Goldberg GS.
-
Journal Title
Oncotarget.
Volume: 6(11)
Issue: 11
Pages: 9045-9060
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
[Journal Article] Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin.2015
Author(s)
Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y.
-
Journal Title
Monoclon Antib Immunodiagn Immunother.
Volume: 34(5)
Issue: 5
Pages: 318-326
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-